


PHARMACEUTICAL 2022



Mirati Therapeutics Inc. Rank 237 of 475





PHARMACEUTICAL 2022



Mirati Therapeutics Inc. Rank 237 of 475

The relative strengths and weaknesses of Mirati Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Mirati Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 127% points. The greatest weakness of Mirati Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 105% points.

The company's Economic Capital Ratio, given in the ranking table, is -93%, being 184% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	1,507,983
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	143,658
Liabilities, Non-Current	48,058
Other Assets	64,947
Other Compr. Net Income	-691
Other Expenses	3,299
Other Liabilities	0
Other Net Income	-5,304
Property and Equipment	15,824
Research and Development	508,594
Revenues	72,092
Selling, General and Administrative Expense	136,679

Output Variable	Value in 1000 USD
Assets	1,588,754
Liabilities	191,716
Expenses	648,572
Stockholders Equity	1,397,038
Net Income	-581,784
Comprehensive Net Income	-582,130
Economic Capital Ratio	-93%